Tissue testing firm raises fresh funding

INVESTORS have pumped a further £270,000 into a contract research organisation spun out of Glasgow Caledonian University (GCU).

Perth-based Braveheart Investment Group, angel investor network Tri Cap and Scottish Enterprise's co-investment fund all took part in the funding round for Biopta, which was launched from GCU in 2002.

Biopta uses human tissues to better predict drug safety and efficacy prior to clinical trials. Its clients include eight of the top ten global pharmaceutical companies.

Aim-listed Braveheart first invested in Biopta in 2004. The latest cash will help with marketing costs and diversification.

Geoffrey Thomson, chief executive of Braveheart, said: "Biopta is an established brand in human tissue testing and we are pleased to support the company."